CVS Delivers Beat-and-Raise, Executing on Turnaround

What happened

CVS Health outperformed peers with a Q1 beat-and-raise, projecting margin expansion and low-double-digit investor returns for 2026. The company's Health Services and Insurance segments are on track for mid-single-digit growth, while retail faces gradual decline but with improving margins. This positive performance comes despite industry headwinds and builds on a restructuring plan targeting >$500M in 2025 savings. However, near-term earnings were pressured by $833M in litigation charges in Q2 2025, and PBM regulatory risk remains an overhang. Overall, CVS is executing well operationally, but investors should remain cautious on legal and regulatory uncertainties.

Implication

The beat-and-raise reinforces CVS's turnaround narrative, with margin expansion and cash flow guidance supporting the stock's low valuation. However, the $833M litigation charge in Q2 2025 and ongoing PBM regulation threats mean that near-term gains are limited. Investors should monitor Medicare utilization trends and regulatory developments closely. The long-term thesis depends on successful scaling of transparent pricing models (TrueCost, CostVantage) and further cost savings. If these execute well, CVS could re-rate higher; otherwise, risks remain.

Thesis delta

The BUY stance is reinforced by Q1's beat-and-raise and margin expansion guidance, shifting focus from headwinds to execution. Litigation charges and regulatory risks remain, but the operational improvement reduces near-term downside. The thesis now hinges more on successful restructuring and pricing model adoption than on macro headwinds.